Discover open access scientific publications

Search, annotate, share and cite publications

Publications by F S Pedersen

Complementation of a Primer Binding Site-Impaired Murine Leukemia Virus-Derived Retroviral Vector by a Genetically Engineered tRNA-like Primer.

Journal of Virology

English

Chimeras of Receptors for Gibbon Ape Leukemia Virus/Feline Leukemia Virus B and Amphotropic Murine Leukemia Virus Reveal Different Modes of Receptor Recognition by Retrovirus.

English

Second-Site Proviral Enhancer Alterations in Lymphomas Induced by Enhancer Mutants of SL3-3 Murine Leukemia Virus: Negative Effect of Nuclear Factor 1 Binding Site.

English

Stability of AML1 (Core) Site Enhancer Mutations in T Lymphomas Induced by Attenuated SL3-3 Murine Leukemia Virus Mutants.

English

Sequence Tags of Provirus Integration Sites in DNAs of Tumors Induced by the Murine Retrovirus SL3-3.

English

Increased Lymphomagenicity and Restored Disease Specificity of AML1 Site (Core) Mutant SL3-3 Murine Leukemia Virus by a Second-Site Enhancer Variant Evolved in Vivo.

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by F S Pedersen

Complementation of a Primer Binding Site-Impaired Murine Leukemia Virus-Derived Retroviral Vector by a Genetically Engineered tRNA-like Primer.

Chimeras of Receptors for Gibbon Ape Leukemia Virus/Feline Leukemia Virus B and Amphotropic Murine Leukemia Virus Reveal Different Modes of Receptor Recognition by Retrovirus.

Second-Site Proviral Enhancer Alterations in Lymphomas Induced by Enhancer Mutants of SL3-3 Murine Leukemia Virus: Negative Effect of Nuclear Factor 1 Binding Site.

Stability of AML1 (Core) Site Enhancer Mutations in T Lymphomas Induced by Attenuated SL3-3 Murine Leukemia Virus Mutants.

Sequence Tags of Provirus Integration Sites in DNAs of Tumors Induced by the Murine Retrovirus SL3-3.

Increased Lymphomagenicity and Restored Disease Specificity of AML1 Site (Core) Mutant SL3-3 Murine Leukemia Virus by a Second-Site Enhancer Variant Evolved in Vivo.